In addition, among other biomarker candidates, endogenous antioxidant CART is very promising since deficits in serotonergic and dopaminergic pathways seem more pronounced in DLB patients, and CART can modulate these pathways [132]. The gene discussed is CARTPT; the disease is Lewy body dementia.